5-Fluorouracil: A pharmacological paradigm in the use of cytotoxics

Clinical and Experimental Pharmacology and Physiology

Volumn 25, Issue 11, 1998, Pages 887-895

  Thomas, D M ^a   Zalcberg, J R ^b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

5 Fluorouracil; Biomodulation; Chronotherapy; Clinical outcomes; Locoregional chemotherapy; Oral bioavailability; Pharmacological manipulation

Indexed keywords

5 ETHYNYLURACIL; CAPECITABINE; CISPLATIN; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; INTERFERON; LEVAMISOLE; METHOTREXATE; TEGAFUR; URACIL;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CHRONOTHERAPY; CIRCADIAN RHYTHM; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER CLEARANCE; METASTASIS INHIBITION; MUCOSA INFLAMMATION; ORAL DRUG ADMINISTRATION; REVIEW;

EID: 0031796275     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.1998.tb02339.x     Document Type: Review

References (71)

1. Heidelberger C, Chandhari NK, Dannenberg P et al. Fluorinated pyrimidines: A new class of tumour inhibitory compounds. Nuture 1957; 179: 663-6.
2. Johnston PG, Fisher ER, Rockette HE et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J. Clin. Oncol. 1994; 12: 2640-7.
3. Finch RE, Bending MR, Lant AF. Plasma levels of 5-fluorouracil after oral and intravenous administration in cancer patients. Br. J. Clin. Pharmacol. 1979; 7: 613-17.
4. Cohen JL, Irwin LE, Marshall GJ et al. Clinical pharmacology of oral and intravenous 5-fluorouracil (NSC-19893). Cancer Chemother. Rep. 1974; 58: 723-31.
5. Heggie GD, Sommadossi J-P, Cross DS et al. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 1987; 47: 2203-6.
6. Grem JL. 5-Fluoropyrimidines. In: Chabner BA, Longo DL (eds). Cancer Chemotherapy and Biotherapy: Principles and Practice, 2nd edn. Lippincott-Raven, Philadelphia. 1996; 149.
7. Ettienne MC, Cheradame S, Fischel JL et al. Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity. J. Clin. Oncol. 1995; 13: 1663-70.
8. Harris BE, Carpenter JT, Diasio RB. Severe toxicity secondary to dihydropyrimidine dehydrogenase deficiency. Cancer 1991; 68: 499-501.
9. Wei X, McLeod HL, McMurrough J et al. Molecular bias of human dihydropyrimidine dehydrogenase deficiency and fluorouracil toxicity. J. Clin. Invest. 1996; 98: 610-15.
10. Lu ZH, Zhang R, Diasio RB. Comparison of dihydropyrimidine dehydrogenase from human, rat, pig and cow liver. Biochemical and immunological properties. Biochem. Pharmacol. 1994; 46: 945-52.
11. Sobrero AF, Aschele C, Bertino JR. Fluorouracil in colorectal cancer: A tale of two drugs. Implications for biochemical modulation. J. Clin. Oncol. 1997; 15: 368-81.
12. Aschele C, Sobrero A, Faderan M et al. Novel mechanisms of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res. 1992; 52: 1855-64.
13. Nord LD, Martin DS. Loss of tumor thymidine kinase activity in vivo following 5-fluorouracil (FUra) treatment by incorporation of FUra into RNA. Biochem. Pharmacol. 1991; 42: 2369-75.
14. Labianca R, Beretta G, Clerici M et al. Cardiac toxicity of 5-fluorouracil: A study on 1083 patients. Tumori 1982; 68: 505-10.
15. Buyse M, Zeleniuch-Jacquotte A, Chalmers TC. Adjuvant therapy for colorectal cancer: Why we still don't know. JAMA 1988; 259: 3571-8.
16. Allegra CJ, Grem JL. Antimetabolites. In: DeVita VT, Hellman S, Rosenberg SA (eds). Cancer: Principles and Practice of Oncology, 5th edn. Lippincott-Raven, Philadelphia. 1997; 432-52.
17. Piedbois P, Buyse M, Blijham G et al. Meta-analysis of randomised trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colon cancer for the Advanced Colorectal Cancer Metaanalysis Project. J. Clin. Oncol. 1994; 12: 960-9.
18. Schabel Jr FM, Trade MW, Laster WR et al. Cis-dichlorodiamine-platinum (II): Combination chemotherapy and cross-resistance studies with tumours of mice. Cancer Treat. Rep. 1979; 63: 1459-73.
19. Scanlon KJ, Newman EM, Priest DG. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc. Natl Acad. Sci. USA 1986; 83: 8923-5.
20. Pratesi G, Gianni L, Manzotti C, Zunino F. Sequence dependence of the antitumor and toxic effects of 5-fluorouracil and cis-diaminedichloroplatinum combination on primary colon tumors in mice. Cancer Chemother. Pharmacol. 1988; 21: 237-40.
21. Esaki T, Kanano S, Tatsumoto T et al. Inhibition by 5-fluorouracil of cis-diaminedichloroplatinum (II)-induced DNA interstrand cross-link removal in a newly established HST-1 human squamous carcinoma cell line. Cancer Res. 1992; 52: 6501-6.
22. Sotos GA, Grogan L, Allegra CJ. Pre-clinical and clinical aspects of biomodulation of 5-fluorouracil. Cancer Treat. Rev. 1994; 20: 11-49.
23. Kemeny NE, Israel K, Niedzwiecki D et al. Randomised study of continuous infusion 5-fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer. J. Clin. Oncol. 1990; 8: 313-18.
24. De Gramont A, Vignoud J, Tournigrand C et al. Oxaliplatin with high-dose folinic acid and 5-fluorouracil 48 hr infusion in pre-treated metastatic colorectal cancer (CRC). Eur. J. Cancer 1997; 33: 214-19.
25. Wadler S, Schwartz EL. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies. Cancer Res. 1990; 50: 3473-86.
26. Chu E, Zinn S, Boarman D, Allegra CJ. Interaction of gamma-interferon and 5-fluorouracil in the H630 human colon carcinoma cell line. Cancer Res. 1990; 50: 5834-40.
27. Grem JL, Chu E, Boarman D et al. Biochemical modulation of fluorouracil with folinic acid and interferon. Semin. Oncol. 1992; 19: 36-44.
28. Danhauser LL, Freimann JH, Gilchrist TL et al. Phase 1 and plasma pharmacokinetic study of infusional 5-fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer. J. Clin. Oncol. 1993; 11: 751-61.
29. Schwartz EL. Hoffman M, O'Connor CJ, Wadler S. Stimulation of 5-fluorouracil metabolic activation by interferon-alfa in human colon carcinoma cells. Biochem. Biophys. Res. Commun. 1992; 182: 1232-9.
30. Hill M, Norman A, Cunningham D et al. Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. J. Clin. Oncol. 1995; 13: 1297-302.
31. Corfu-A Study Group. Phase III randomised study of two fluorouracil combinations with either interferon alfa-2a or folinic acid for advanced colorectal cancer. J. Clin. Oncol. 1995; 13: 921-8.
32. Herskovic A, Martz K, Al-Sarraf M et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N. Engl. J. Med. 1992; 326: 1593-8.
33. O'Connell MJ, Martenson JA, Wieand HS et al. Improving adjuvant therapy for rectal cancer by combining protracted infusion fluorouracil with radiation therapy after curative surgery. N. Engl. J. Med. 1994; 331: 502-7.
34. Gastrointestinal Study Group. Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J. Natl Cancer Inst. 1988; 80: 751-5.
35. Moertel CG, Frytak S, Hahn RG er al. Therapy of locally unresectable pancreatic carcinoma: A randomised comparison of high-dose (6000rads) radiation alone, moderate dose radiation (4000rads) + 5-fluorouracil and high-dose radiation + 5FU, Cancer 1981; 48: 1705-10.
36. Danenberg PV, Danenberg KD. Effect of 5,10-methylenetetrahydrofolate on the dissociation of 5-fluoro-2′-deoxyuridylate from thymidylate synthase: Evidence for an ordered mechanism. Biochemistry 1978; 17: 4018-24.
37. Evans RM, Laskin JD, Hakala MT. Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Res. 1981; 41: 3288-95.
38. Swain SM, Lippman ME, Egan EF et al. 5-Fluorouracil and high-dose folinic acid in previously treated patients with metastatic breast cancer. J. Clin. Oncol. 1989; 7: 890-9.
39. Boarman DM, Allegra CJ. Intracellular metabolism of 5-formyltetrahydrofolate in human breast and colon cell lines. Cancer Res. 1992; 52: 36-44.
40. Advanced Colorectal Cancer Metaanalysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J. Clin. Oncol 1992; 10: 896-903.
41. Petrelli N, Douglass HO, Herrera L et al. The modulation of fluorouracil with folinic acid in metastatic colorectal carcinoma: A prospective randomised phase III trial, J. Clin, Oncol. 1989; 7: 1419-20.
42. Poon MA, O'Connell MJ, Moertel CG et al. Biochemical modulation of fluorouracil: Evidence of significant improvement in survival and quality of life in patients with advanced colorectal carcinoma. J. Clin. Oncol. 1989; 7: 1407-17.
43. Wolmark N, Rockette H, Fischer B et al. The benefit of folinic acid-modulated fluorouracil as a post-operative adjuvant therapy for primary colon cancer: Results from the National Surgical Adjuvant Breast and Bowel Project C-03. J. Clin. Oncol. 1993; 11: 1879.
44. O'Connell MJ, Maillard JA, Kahn MJ et al. Controlled trial of 5-FU and low-dose folinic acid as postoperative, adjuvant therapy for colon cancer. J. Clin. Oncol. 1997; 15: 246-50.
45. Francini GP, Lorenzini L. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 1994; 106: 899.
46. Labianca R, Pancera G, Aitini C et al. Folinic acid + 5-fluorouracil versus equidose 5-FU in advanced colorectul cancer. Phase III study of GISCAD (Italian Group for the Study of Digestive Tract Cancer). Ann. Oncol. 1991; 2: 673-9.
47. Lokich JJ, Ahlgren JD, Gullo JJ et al. A prospective randomised comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectul carcinoma: A Mid-Atlantic Oncology Program study. J. Clin. Oncol. 1989; 7: 425-32.
48. Ross PJ, Webb A, Cunningham D et al. Infusional 5-fluorouracil in the treatment of gastrointestinal cancers: The Royal Marsden Hospital experience. Ann. Oncol. 1997; 8: 111-15.
49. Webb A, Cunningham D. Scarffe JH et al. Randomised trial comparing epirubicin, csiplatin and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced oesophagogastric cancer. J. Clin. Oncol. 1997; 15: 261-7.
50. Mori A, Bertoglio S, Guglielmo A et al. Activity of continuous infusion 5-fluorouracil in patients with advanced colorectal cancer resistant to bolus 5-fluorouracil. Cancer Chemother. Pharmacol. 1993; 33: 179-80.
51. Breedis C, Young C. The blood supply of the liver. Am. J. Pathol. 1954; 30: 969-85.
52. Ensminger WD, Rosowsky A, Raso VO et al. A clinical pharmacological evaluation of hepatic arterial infusion of 5-fluoro-2′-deoxyuridine and 5-fluorouracil. Cancer Res. 1978; 38: 3784-92.
53. Kemeny N, Lokich JJ, Anderson N, Ahlgren JD. Recent advances in the treatment of advanced colorectal cancer. Cancer 1993; 71: 9-18.
54. Penna C, Nordlinger B. Locoregional chemotherapy for adjuvant treatment of colorectal adenocarcinonia. Eur. J. Cancer 1996; 32A: 1117-22.
55. Wolmark N, Rockette H, Wickerman DL et al. Adjuvant therapy of Duke's A, B and C adenocarcinoma of the colon with portal vein, fluorouracil hepatic infusion: Preliminary results of NSABP C-02. J. Clin. Oncol. 1990; 8: 1466-75.
56. Muggia FM, Chan KK, Russell C et al. Phase I and pharmacologic evaluation of intraperitoneal cisplatin and fluorouracil in patients with, advanced intra-abdominal cancer. J. Clin. Oncol. 1990; 8: 2054.
57. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous chemotherapy. J. Clin. Oncol. 1997; 15: 110-15.
58. Porter DJT, Chestnut WG, Merrill BM, Spector T. Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil. J. Biol. Chem. 1992; 267: 5236-42.
59. Baker SD, Khor SP, Adjei AA et al. Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J. Clin. Cancer 1996; 14: 3085-96.
60. Cao S, Rustum YM, Spector T. 5-Ethynyluracil (776C85): Modulation of 5-FU efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res. 1994; 54: 1507-10.
61. Spector T, Cao S, Rustum YM, Harrington JA, Porter DJ. Attenuation of antitumor activity of 5-FU by R-5-fluoro-5,6-dihydrouracil. Cancer Res. 1995; 55: 1239-41.
62. Fuji S, Ikenaka K, Fukushima M, Shirasaka T. Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-terahydrofuryl)-5-fluorouracil. Gann 1978; 69; 763-72.
63. Ota K, Taguchi T, Kimura K. Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother. Pharmacol. 1988; 22: 333-8.
64. Ishitsuka H, Miwa M, Ishikawa T et al. Capecitabine: An orally available fluoropyrimidine with tumor selective activity. Proc. Am. Assoc. Cancer Res. 1995; 36: 407.
65. Harris B, Song R, Soong S, Diasio RB. Circadian variation of 5-fluorouracil catabolism in the isolated perfused rat. Cancer Res. 1989; 49: 6610-14.
66. Buchi KN, Moore JG. Hrushesky WJM et al. Circadian rhythm of cellular proliferation in the human rectal mucosa. Gastroenterology 1991; 101: 410-15.
67. Smaaland R, Laerum OD, Sothern RB et al. Colony-forming unit-granulocyte-macrophage and DNA synthesis of human bone marrow are circadian stage-dependent and show covariation. Blood 1992; 79: 2281-7.
68. Roemeling R, Hrushesky WM. Cirrcadian patterning of continuous floxuridine infusion reduces toxicity and allows higher dose intensity in patients with widespread cancer. J. Clin. Oncol. 1989; 7: 1710-19.
69. Adler S, Lang S, Langenmayer I et al. Chronotherapy with 5-fluorouracil and folinic acid in advanced colorectal carcinoma: Results of a chronopharmacologic phase I trial. Cancer 1994: 73: 2905-12.
70. Levi F, Zidani R, Vannetzel JM et al. Chronomodulated versus fixed infusion rate delivery of ambulatory chemotherapy with oxaliplatin. 5-fluorouracil and folinic acid in patients with colorectal cancer metastases: A randomised multi-institutional trial. J. Natl Cancer Inst. 1994; 86: 1608-17.
71. Levi F, Zidani R, Misset JL et al. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil and folinic acid in metastatic colorectal cancer. Lancet 1997; 350: 681-6.